Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
Abnormal Karyotype
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Chromosome Aberrations
Comparative Genomic Hybridization
Disease Management
Female
Follow-Up Studies
Genetic Association Studies
Genetic Predisposition to Disease
Humans
In Situ Hybridization, Fluorescence
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Male
Middle Aged
Mutation
Prognosis
Risk Factors
ATM
Chronic lymphocytic leukemia (CLL)
Complex karyotype
Cytogenetics
TP53
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
09
06
2019
revised:
12
08
2019
accepted:
13
08
2019
pubmed:
3
9
2019
medline:
27
5
2020
entrez:
3
9
2019
Statut:
ppublish
Résumé
A complex karyotype (CK) is considered a poor prognostic marker in chronic lymphocytic leukemia (CLL). The study analyzed 644 untreated CLL patients (pts) using conventional/molecular cytogenetics to reveal the presence of a CK and its composition and to assess its predictive value. The mutational status ofTP53 was detected by next generation sequencing. A CK was detected in 79 pts (12.3%). Patients with a CK showed shorter overall survival (OS) compared to those without a CK (77 months vs. 115 months, p < 0.0001). Chromosomes most frequently included in a CK were 13, 11, 17, 8, 2, and 6. The most common aberrations in a CK were translocations, numerical changes and dicentric chromosomes (with no effect on OS). Patients with aberrations ofTP53 and ATM were shown to have adverse prognosis comparable to patients with a CK without these abnormalities. A stronger impact of a CK on OS of female and older CLL patients was observed. The determining of the presence of a CK is essential in modern clinical CLL practice. According to recent studies, the presence of a CK affects clinical and treatment decision-making.
Identifiants
pubmed: 31476701
pii: S0145-2126(19)30163-8
doi: 10.1016/j.leukres.2019.106218
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106218Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.